EGFR and non-small cell lung carcinoma: The efficacy of tepotinib on NSCLC with T790M-negative MET amplification and/or c-MET overexpression after first/second-generation EGFR–TKI resistance is limited, with a mPFS of only 4.9 months [76,77].